CULVER CITY, Calif.ImmunityBio, Inc. (NASDAQ: IBRX Highlighting these breakthroughs, a series of three enlightening podcasts were recently published on UroToday. These podcasts centered around an in-depth discussion with Patrick Soon-Shiong, M.D. Executive Chairman and Global Chief Scientific at ImmunityBio, and Dr. Ashish Kamat, an esteemed urologist. The focus’ The FDA’s recent approval of ANKTIVA (N-803, or nogapendekin alfa inbakicept-pmln) in conjunction with Bacillus Calmette-Guerin (BCG) for treating non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), as well as other promising advancements in bladder cancer research.
ANKTIVA and BCG: A Revolutionary Combination
The synergistic combination of ANKTIVA and BCG represents a pivotal evolution in the treatment of NMIBC. ANKTIVA, an interleukin-15 (IL-15) superagonist, supercharges the immune system by stimulating natural killer (NK) cells and T-cells. This effect is further magnified when paired with BCG, a long-standing immunotherapy, leading to a more potent anti-tumor response.
Dr. Patrick Soon-Shiong elaborated on the science and impact of this combination in the podcasts, underscoring the groundbreaking nature of ImmunityBio’s Triangle Offense’comprising ANKTIVA, BCG, and a potent activation of the immune system. He explained how this triad effectively targets the cancer cells, thereby reducing recurrence rates significantly as compared to existing treatments.
ImmunityBio’s Triangle Offense aims to turn the tides of non-muscle invasive bladder cancer by harnessing the full potential of the body’s immune system to fight cancer at the cellular level, said Dr. Soon-Shiong. Through these discussions, both Dr. Soon-Shiong and Dr. Kamat provided invaluable insights into the promising future that this treatment holds for NMIBC patients.
Scaling Up for Success
However, successful treatments require strategic planning and execution, particularly in terms of manufacturing and IBRX ImmunityBio has proven its capability to scale by completing the good manufacturing practice (GMP) drug substance (DS) production sufficient for 170,000 doses of ANKTIVA.
This accomplishment removes a significant bottleneck in the distribution pipeline, enhancing the availability of ANKTIVA. This feat doesn’t just signify the readiness of the company but also sets the stage for meeting anticipated demand, ensuring that patients worldwide can benefit from these cutting-edge treatments.
Moreover, coupling this with ImmunityBio’s exclusive arrangement with the Serum Institute of India (SII) marks a monumental stride in securing a stable and quality-controlled supply of BCG. The Serum Institute of India, being the global leader in vaccine manufacturing, will now be producing both standard BCG (sBCG) approved for use outside the U.S. and a next-generation recombinant BCG (iBCG) planned for use in combination with ANKTIVA.
This collaboration fortifies ImmunityBio’s supply chain, ensuring the continuous and undisrupted availability of both components of its novel therapeutic regimen.
Gearing Up for Global Impact
The partnership between ImmunityBio and the Serum Institute of India is more than just a strategic alliance; it represents a pledge to uplift cancer treatment standards globally. The availability of ANKTIVA and BCG on a global scale signifies an equitable distribution of innovative therapies, bringing hope to many.
“Through this partnership, we aim to make substantial advancements in the treatment of bladder cancer worldwide. We are dedicated to ensuring that these life-saving treatments are within reach of every patient in need,” affirmed Dr. Soon-Shiong.
In the series of UroToday podcasts, both doctors not only highlighted the clinical importance of ANKTIVA but also emphasized its broader implications for global health. The alignment of advanced scientific research, robust manufacturing protocols, and supply chain excellence underscores ImmunityBio’s commitment to defeating cancer through innovative immunotherapies.
Comments